Drug Sponsors

Bayer to acquire Steigerwald Arzneimittelwerk

Friday, May 17, 2013 11:56 AM

Bayer has signed an agreement to acquire 100% of the shares of Steigerwald Arzneimittelwerk, a Darmstadt, Germany-based privately held pharmaceutical company specializing in pharmacy-only herbal medicines.

More... »

Astellas outlines plan to reshape its research framework, reallocate resources

Tuesday, May 14, 2013 02:44 PM

Tokyo-based Astellas Pharma has announced plans to reshape its research framework by introducing new initiatives to enhance the ability to generate innovative drugs.

More... »

GSK deal aims to grow business in Asia

Tuesday, May 14, 2013 01:30 PM

DKSH's Business Unit Healthcare, a market expansion services provider for healthcare companies seeking to grow their business in Asia, has signed an agreement with GlaxoSmithKline to provide contract sales services in both private clinics and trade channel for its antibiotic product line.

More... »

Elan CEO says $1 billion royalty deal with Theravance a unique opportunity

Tuesday, May 14, 2013 01:12 PM

Elan has announced a royalty agreement with Theravance, by which Elan will make a one-time cash payment of $1 billion to Theravance in exchange for a 21% participation interest in the potential future royalty payments from four respiratory programs for which Theravance has partnered with GlaxoSmithKline, when and if received by Theravance.

More... »

Quintiles prices IPO at $40 per share

Thursday, May 9, 2013 11:40 AM

Quintiles has announced the pricing of its initial public offering of 23,684,210 shares of its common stock at a price to the public of $40.00 per share. The shares of Quintiles common stock are expected to begin trading on the New York Stock Exchange under the single-letter symbol "Q” on May 9, 2013.  

More... »

Takeda to acquire Inviragen

Thursday, May 9, 2013 10:38 AM

Takeda Pharmaceutical has signed a definitive agreement to acquire Inviragen for an upfront payment of $35 million, and future payments of up to $215 million linked to the progress of clinical development and achievement of key commercial milestones.

More... »

NeuroPhage raises $6.4M in additional financing

Monday, May 6, 2013 02:40 PM

NeuroPhage Pharmaceuticals, a company developing breakthrough therapies for neurodegenerative diseases, has raised $6.4 million in a private equity financing round. Mérieux Développement led the financing with participation from all current Neurophage investors, including Shire.  

More... »

AltheRx raises $15M, names Jim Bennethum CEO, appoints new board of directors

Monday, May 6, 2013 10:41 AM

AltheRx Pharmaceuticals, a privately-held clinical development company, announced a restructuring that includes a $15 million financing, the appointment of Jim Bennethum as CEO, and the appointment of a new board of directors.

More... »

Natera completes $54.6M financing for global rollout of Panorama prenatal test

Wednesday, May 1, 2013 02:46 PM

Natera, a genetic testing company, has completed a $54.6 million financing round to support the expansion and continued global rollout of Natera's non-invasive prenatal test, Panorama. The financing round included two new lead investors, OrbiMed Advisors and Harmony Partners, as well as other undisclosed new investors. All existing investors participated, including Claremont Creek Ventures, Lightspeed Venture Partners, Founders Fund and Sequoia Capital.

More... »

Aerocrine completes $50M debt and equity financing

Wednesday, May 1, 2013 10:58 AM

Aerocrine, a medical products company, has completed a financing with an affiliate of the U.S. investment firm OrbiMed Advisors and with Novo consisting of $35 million of debt. Aerocrine also raised $ 15 million of equity from OrbiMed and a number of institutional investors through a directed share issue.

More... »